Singular Health Group Ltd. announced that Singular Health's Chief Executive Officer and Managing Director, Mr. Thomas Hanly, has tendered his resignation effective as of 14th April 2023. Mr. Denning Chong, a co-founder, and Non-Executive Director of Singular Health, has been
appointed as Interim Chief Executive Officer and Managing Director and shall work with the Board and senior management during this transition process until a new Chief Executive Officer is appointed. Mr. Chong will immediately commence a strategic review of the Company's activities, with a focus on streamlining efficiencies, reducing expenditure, and prioritising the finalisation and execution of the numerous global commercial opportunities currently in progress by the Company. Having joined Singular Health as the Managing Director and Chief Executive Officer in 2019, Mr. Hanly has played a pivotal role in the initial foundation building of the Company, the product roadmap and the Company's various commercial milestones such as the highly successful IPO in February 2021, and more recently the FDA regulatory clearance in October 2022, the Global3D acquisition completed in January 2023, the Sony collaboration and the ISO13485 certification in March 2023. Mr. Hanly shall remain engaged by the Company as a consultant on certain strategic matters and R&D activities.